<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04950153</url>
  </required_header>
  <id_info>
    <org_study_id>iCARE Nigeria UH3</org_study_id>
    <secondary_id>UH3HD096920</secondary_id>
    <nct_id>NCT04950153</nct_id>
  </id_info>
  <brief_title>Intensive Combination Approach to Rollback the Epidemic in Nigerian Adolescents: UH3 Phase</brief_title>
  <acronym>iCARE</acronym>
  <official_title>Intensive Combination Approach to Rollback the Epidemic in Nigerian Adolescents: UH3 Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combination interventions with mHealth and Peer Navigation components will be evaluated in a&#xD;
      randomized, stepped wedge trial among youth in Ibadan, Lagos, Sagamu, and Jos, Nigeria. Study&#xD;
      findings will demonstrate whether or not the combination interventions for HIV testing and&#xD;
      linkage to care and for HIV treatment outcomes, which were found to be efficacious in our&#xD;
      prior pilot UG3 trial, will remain efficacious if scaled as proposed in this UH3 trial,&#xD;
      across multiple sites.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized stepped wedge (cluster) trial will be conducted to investigate two combination&#xD;
      interventions (each with mHealth + Peer Navigation components) among youth in Ibadan, Lagos,&#xD;
      Sagamu, and Jos, Nigeria. Study 1 (Testing and Linkage to Care) will test a combination&#xD;
      intervention that targets HIV testing and linkage to care. Study 2 (Treatment Intervention)&#xD;
      will test a combination intervention that targets HIV treatment outcomes (retention,&#xD;
      adherence and viral suppression).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Stepped wedge (cluster) randomized trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VIral suppression</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of participants with viral suppression, defined as viral load (plasma HIV-1 RNA) &lt;200 copies/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antiretrovial adherence measured by pharmacy drug pick-up</measure>
    <time_frame>Week 48</time_frame>
    <description>Pharmacy drug pick-up (90% of days with medication)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiretroviral drug concentration</measure>
    <time_frame>Week 48</time_frame>
    <description>Antiretroviral drug concentration in Dried Blood Spot sufficient for viral suppression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention in care</measure>
    <time_frame>Week 48</time_frame>
    <description>Retention, defined as at least two care (non-study) visits in the prior 24-week period</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HIV testing and seroprevalence among young men across multiple sites</measure>
    <time_frame>Week 48</time_frame>
    <description>HIV seroprevalence among the tested young men during the intervention period (the number of confirmed HIV cases divided by the total number of tests).</description>
  </other_outcome>
  <other_outcome>
    <measure>Linkage of newly diagnosed young men to a clinic for ART</measure>
    <time_frame>48 weeks</time_frame>
    <description>Percentage of young men who are linked to HIV care within 30 days of an HIV confirmatory test</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Adolescent HIV Infection</condition>
  <arm_group>
    <arm_group_label>HIV Testing Intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Combination HIV testing and linkage to care intervention includes social media engagement and peer navigation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV Treatment Intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Combination HIV treatment outcomes (retention, ART adherence and viral suppression) intervention includes SMS text messaging and peer navigation</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Peer navigation</intervention_name>
    <description>Peer navigators will navigate youth with HIV to provide assistance and support to optimize adherence to antiretroviral treatment (ART)</description>
    <arm_group_label>HIV Treatment Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>SMS Text messaging</intervention_name>
    <description>Short Message System (SMS) text messages to remind and encourage youth to adhere to their ART</description>
    <arm_group_label>HIV Treatment Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Social Media Engagement</intervention_name>
    <description>HIV testing outreach using social media platforms to promote HIV testing.</description>
    <arm_group_label>HIV Testing Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Testing Peer Navigation</intervention_name>
    <description>Peer navigators will conduct HIV testing outreach and linkage to care to at-risk youth</description>
    <arm_group_label>HIV Testing Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Living with HIV infection&#xD;
&#xD;
          -  Registered in the study clinics or their satellite clinics&#xD;
&#xD;
          -  On antiretroviral therapy (ART) for at least 3 months&#xD;
&#xD;
          -  Intention to remain a study clinic patient during the study observation and&#xD;
             intervention period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Youths who are 15 years old and not emancipated, who do not have parental consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Babafemi Taiwo, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Garofalo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ann &amp; Robert Lurie Childrens Hospital of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Babafemi Taiwo, MBBS</last_name>
    <phone>312-695-0009</phone>
    <email>b-taiwo@northwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Baiba Berzins, MPH</last_name>
    <phone>312-695-5012</phone>
    <email>baiba@northwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Ibadan</name>
      <address>
        <city>Ibadan</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olayinka Omigbodun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jos University Teaching Hospital</name>
      <address>
        <city>Jos</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oche Agbaji, MBBS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lagos State University Teaching Hospital</name>
      <address>
        <city>Lagos</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akinsegun Akinbami, MBBS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lagos University Teaching Hospital</name>
      <address>
        <city>Lagos</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alani S Akanmu, MBBS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nigerian Institute of Medical Research (NIMR)</name>
      <address>
        <city>Lagos</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agatha David, MBBS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Olabisi Onabanjo University Teaching Hospital</name>
      <address>
        <city>Sagamu</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Folashade Adekanmbi, MBBS</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Nigeria</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 25, 2021</study_first_submitted>
  <study_first_submitted_qc>June 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Babafemi Taiwo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

